TLDR
- FDA approved Kresladi, then RCKT stock dropped 19% in hours.
- Rocket Pharma won FDA approval and lost 19% of its stock value same day.
- RCKT got its biggest win ever and the market punished it hard for it.
- Sell-the-news hits RCKT: FDA approves Kresladi, stock drops to $3.79.
- Kresladi is FDA-approved. RCKT is down 19%. Biotech logic at its finest.
Rocket Pharmaceuticals (RCKT) stock fell sharply today, trading at $3.79, down 19.19%. The FDA approved KRESLADI, the company’s gene therapy for severe LAD-I, just a day before. Yet the RCKT stock drop came right at market open, confusing many who expected a rally.
Rocket Pharmaceuticals, Inc., RCKT
FDA Grants Accelerated Approval for Kresladi A Rare Pediatric Breakthrough
Rocket Pharmaceuticals secured a landmark FDA accelerated approval for Kresladi on March 26, 2026. Kresladi treats severe leukocyte adhesion deficiency-I, or LAD-I, a rare and life-threatening pediatric disease. This makes RCKT one of the few biotechs to win approval for this ultra-rare genetic condition.
LAD-I affects roughly one in 100,000 to 200,000 live births in the United States. About two-thirds of those patients carry the severe form of the disease. Children with severe LAD-I face repeated bacterial and fungal infections that standard antibiotics cannot control.
Kresladi works by correcting mutations in the ITGB2 gene, which encodes the CD18 protein. This protein helps white blood cells fight infections and heal wounds. Without it, the immune system fails to protect the body effectively.
RCKT Stock Reaction Signals Classic Sell-the-News Pressure
RCKT stock opened near its prior close but fell sharply around market open on March 27. The chart showed a cliff drop between 9:00 AM and 11:00 AM EDT. This pattern is consistent with traders exiting after a long-anticipated catalyst finally arrived.
The PDUFA date for Kresladi was set for March 28, 2026. So the early approval caught some off-guard, but the sell-off suggests many had already priced in a win. RCKT had previously received a Complete Response Letter from the FDA in 2024 over manufacturing concerns, which had stalled the stock.
Along with the approval, the FDA granted RCKT a Rare Pediatric Disease Priority Review Voucher. The company said it plans to monetize the voucher to boost financial flexibility. This voucher holds significant value and could provide RCKT with a substantial cash injection.
What This Approval Means for Rocket Pharmaceuticals Long-Term
CEO Gaurav Shah stated the approval reflects years of work by patients, families, and regulators. Principal Investigator Dr. Donald Kohn of UCLA called it the result of years of research and clinical collaboration. Both noted that Kresladi now offers a treatment option where none previously existed for eligible U.S. patients.
The approval carries a post-marketing condition tied to longer-term clinical follow-up. RCKT must confirm clinical benefit through an ongoing study and a post-marketing registry. This means the accelerated status could convert to full approval as data matures.
RCKT trades within a 52-week range of $2.19 to $8.25, reflecting sharp volatility typical of clinical-stage biotechs. The stock’s decline does not erase the commercial significance of the Kresladi win. For RCKT, drop may simply be the market resetting after a long-anticipated event finally closed.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
